Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in Switzerland (SWX: SDZ), has announced the launch of Tyruko (natalizumab), the first biosimilar version of Biogen’s (NASDAQ: BIIB) blockbuster Tysabri, in the German market. This move marks a significant advancement in the treatment options for adults with highly active relapsing remitting multiple sclerosis (RRMS), as both drugs are indicated as disease-modifying therapies (DMT) for this condition.
Sandoz secured the global licensing rights for Tyruko from Poland’s Polpharma Biologics in 2019, and following the European Commission’s (EC) approval of the biosimilar last year, it is now poised to offer a more accessible alternative to patients in need. The introduction of Tyruko into the German market is expected to increase competition, potentially leading to more affordable treatment options for those living with RRMS.- Flcube.com
